Nuformix Share Discussion Threads

[georgeo1] 25/3/2021 00:58

Might hear some progress on NXP002 last news was last October.

[georgeo1] 24/3/2021 22:12

https://youtu.be/u3_tknVV728Only 2 months in the job and making great positive results. background from big pharmas well known in the respiratory field. Way forward now and shareholder value.

[soupdragon55] 24/3/2021 13:30

Well done Richard, very perceptive.

[georgeo1] 24/3/2021 13:22

If it does still not a bad amount issued. With news out prob after announcement. Oxilio moving ahead.

[richardp19] 24/3/2021 13:18

Placing coming

[georgeo1] 24/3/2021 11:00

Sorry just I've received ballot for proposals today.

[soupdragon55] 24/3/2021 10:49

On Monday, not today

[georgeo1] 24/3/2021 10:11

GM today get your votes in.

[soupdragon55] 24/3/2021 00:08

Quotient ran the previous pharmacokinetic trials on NXP001 for NFX.

In essence, NFX don't make anything themselves, they do the academic and research lab work, then outsource to have the drugs made and tested.

[georgeo1] 23/3/2021 23:41

What's the deal with NXP001 so far with this lot..https://www.quotientsciences.com/news/quotient-clinical-signs-agreement-with-nuformix-to/

[georgeo1] 23/3/2021 22:58

Pipeline IPF drugs from FibroGen, Galapagos and PureTech could also generate sales if approved during the COVID recovery period, the analysts said.For kidney disease AstraZeneca, FibroGen, GlaxoSmithKline, Novartis and Travere could see sales increase.

[georgeo1] 23/3/2021 22:43

This pilot study for NXP002 has been performed by FibroFind the University-based service facility embedded in Newcastle Fibrosis Research Group.

[georgeo1] 23/3/2021 22:35

This is where the Covid 19 bit maybe mentioned come in.Pharma poised to cash in on 'long COVID' symptoms?Richard StainesMarch 11, 2021While there's hope that vaccination campaigns may bring the pandemic under control, "long COVID" side effects may continue to affect patients for some time.According to analysts from Jefferies, several pharma companies could stand to benefit with products that could help with issues such as mental health, lung scarring, kidney disease and heart failure.Although in many cases COVID-19 is a respiratory disease, it is known to attack other organs, causing  a range of longer-term problems known as "long COVID".The pandemic has had a significant impact on mental health, according to Jefferies, with doctors questioned in a small survey expecting an increase in anxiety and mood disorders.Conditions most likely to be more commonly presented are major depressive disorder, insomnia, post-traumatic stress disorder and self-harm.Lundbeck with its depression drug Trintellix/Brintellix and its Rexulti schizophrenia drug, which is marketed in partnership with Otsuka, could see sales increase in a post-COVID world.Gedeon Richter and AbbVie with their schizophrenia, bipolar mania and bipolar drug Vraylar could also see sales increase in the mental health crisis, along with a host of other smaller biotechs with potential mental health products such as Idorsia, Relmada and Vistagen.Lung fibrosis (scarring) is another potential side-effect of COVID-19 and Jefferies expects a proportion of survivors to be left with residual functional impairment.Idiopathic pulmonary fibrosis treatments from Roche (Esbriet) and Boehringer Ingelheim (Ofev) could be used but only in the most severe cases due to their side-effects.Pipeline IPF drugs from FibroGen, Galapagos and PureTech could also generate sales if approved during the COVID recovery period, the analysts said.For kidney disease AstraZeneca, FibroGen, GlaxoSmithKline, Novartis and Travere could see sales increase.Heart failure drugs from Novartis (Entresto) and AstraZeneca (Farxiga) are also potential beneficiaries.Overall the companies most likely to benefit from COVID-19 are Sanofi, Novartis, AstraZeneca and GlaxoSmithKline who have a range of products that will be in demand as the pandemic recedes.But companies that will miss out have products focused in the wrong areas with Jefferies' "back of the envelope" analysis suggesting the companies likely to suffer are Novo Nordisk, Merck & Co and Eli Lilly.

[georgeo1] 23/3/2021 22:33

News on Fibrofind research for IPF of Newcastle university. https://pharmaphorum.com/news/big-pharma-could-cash-in-on-long/?_scpsug=crawled,157970,en_1a853b2d680cf7bf795279b7474f1e673827a7dcaca8e17c4300a7c865746c76#_scpsug=crawled,157970,en_1a853b2d680cf7bf795279b7474f1e673827a7dcaca8e17c4300a7c865746c76

[georgeo1] 23/3/2021 16:30

Topped up a few more at this level.

[georgeo1] 23/3/2021 16:29

Monday 29th for general meeting, not going to be at these price any more.

[georgeo1] 23/3/2021 14:26

All other products identical in form but not better than NXP001.On the market are making substantial revenues,once this hits the international markets it's going to be good. On top the cannabis deal with ebers. Only legal in Canada and most of the USA and not the U.K. So yes good times ahead. They also did mention covid 19 but not sure to much detail on that but that's exciting anything to do with covid 19 is always a plus from pharma companies.

[soupdragon55] 23/3/2021 14:10

Ah yes this is the same 'CityAnalyst1' poster who couldn't read a patent correctly and thought Oxilio was a Russian dentist.

Lol. Must try harder.

ps. He even closed that post with the following...

'So, have you managed to join the dots?

Yes, OXL001 is NXP001 and the exercising of the 'option' is not a question of IF but WHEN. To this end, I expect an announcement, shortly, to confirm this alongside the 'significant' upfront payment that is due to Nuformix.

Thus, I only have two words: Substantial Upside.'

[georgeo1] 23/3/2021 13:58

If nfx don't need a placing give refund.

[for fx sake] 23/3/2021 13:29

Just in case I've got it all mixed up, are you talking about the 2p placees who will not be getting those shares until after the resolutions are passed at the EGM on 29th of March?

[ivan danko] 22/3/2021 16:50

You dream too much my friend have some orange juice